Sonus settles class action suit
Sonus Pharmaceuticals has settled a class action suit brought against it in a California Superior Court. The litigation, filed in San Diego, claimed that the company did not communicate clearly about the status of the Food and Drug Administration’s
Sonus Pharmaceuticals has settled a class action suit brought against it in a California Superior Court. The litigation, filed in San Diego, claimed that the company did not communicate clearly about the status of the Food and Drug Administrations clearance of EchoGen, the companys ultrasound contrast agent. Although Bothell, WA-based Sonus believes that the complaint was without merit, it chose to settle rather than engage in the litigation. Terms of the settlement were not disclosed, although Sonus did state that the terms were not monetary.
On the EchoGen front, at the end of September Sonus filed a complete response to conditions outlined in the FDAs approvable letter, which the company received in April (SCAN 4/28/99). Sonus believes that it has provided sufficient answer to the agencys letter, and continues to wait for its response, according to Greg Sessler, CFO.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
